Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
Annals of Hematology|June 23, 2022
Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysisShai Shimony, Jonathan Canaani, Eitan Kugler, et al.
European Journal of Haematology|September 19, 2020
Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remissionYishai Ofran, Ronit Leiba, Avraham Frisch, et al.
American Journal of Hematology|April 9, 2021
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practiceArie Apel, Yakir Moshe, Yishai Ofran, et al.
American Journal of Hematology|May 7, 2016
Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remissionOfir Wolach, Kristen E Stevenson, Martha Wadleigh, et al.
European Journal of Haematology|May 31, 2023
Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemiaJonathan Canaani, Avraham Frisch, Daniel A Pollyea, et al.
Annals of Hematology|June 22, 2022
Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells-single-center experienceOfrat Beyar-Katz, Chava Perry, Yael Bar On, et al.
Annals of Hematology|May 8, 2026
MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AMLNoa Hurvitz, Irina Amitai, Ilana Levy, et al.
American Journal of Hematology|November 2, 2013
Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trialMical Paul, Ron Ram, Eitan Kugler, et al.
Pediatric Blood & Cancer|July 3, 2019
Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood LeukemiaSarah Elitzur, Nira Arad-Cohen, Shlomit Barzilai-Birenboim, et al.
Cancer|August 12, 2023
A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphomaOsnat Bairey, Alisa Taliansky, Amir Glik, et al.
Pageof 10